Browse by author
Lookup NU author(s): Dr Dominic Jones, Professor Martin NobleORCiD, Professor Steve Wedge, Professor Craig Robson, Dr Luke GaughanORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Androgen receptor variants (AR-Vs) provide a mechanism of therapy evasion in castrate-resistant prostate cancer (CRPC), yet mechanisms of regulation remain largely unknown. Here we investigate the role of Aurora A kinase on AR-Vs in models of CRPC and show depletion of Aurora A reduces AR-V target gene expression. Importantly, knockdown of Aurora A reconfigures splicing of AR pre-mRNA to discriminately down-regulate synthesis of AR-V transcripts, including AR-V7, without effecting full-length AR mRNA; and as a consequence, AR-V-driven proliferation and survival of CRPC cells is markedly reduced. Critically, these effects are reproduced by Aurora A inhibition. We show that Aurora A levels increase in advanced disease and AURKA is an AR-V target gene demonstrating a positive feedback mechanism of androgenic signalling in CRPC. In all, our data suggests that Aurora A plays a pivotal role in regulation of AR-V7 expression and represents a new therapeutic target in CRPC.
Author(s): Jones D, Noble M, Wedge SR, Robson CN, Gaughan L
Publication type: Article
Publication status: Published
Journal: Scientific Reports
Year: 2017
Volume: 7
Online publication date: 16/02/2017
Acceptance date: 13/12/2016
Date deposited: 12/04/2017
ISSN (electronic): 2045-2322
Publisher: Nature Publishing Group
URL: https://doi.org/10.1038/srep40957
DOI: 10.1038/srep40957
Altmetrics provided by Altmetric